Inhibition of Myb-dependent gene expression by the sesquiterpene lactone mexicanin-I

Leukemia

Volumn 26, Issue 4, 2012, Pages 615-622

  Bujnicki, T ^a   Wilczek, C ^a   Schomburg, C ^a   Feldmann, F ^a   Schlenke, P ^a   Muller Tidow C ^a   Schmidt, T J ^a   Klempnauer, K H ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

c Myb; inhibitor; mexicanin I; sesquiterpene lactone

Indexed keywords

ANTINEOPLASTIC AGENT; MEXICANIN 1; SESQUITERPENE LACTONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG SCREENING; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; NONHUMAN; ONCOGENE C MYB; ONCOGENE MYB; PRIORITY JOURNAL;

ACETYLTRANSFERASES; ANIMALS; CELL LINE; CELL PROLIFERATION; CHICKENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; K562 CELLS; LACTONES; LEUKEMIA, MYELOID, ACUTE; PROTO-ONCOGENE PROTEINS C-MYB; SESQUITERPENES;

EID: 84859648652     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.275     Document Type: Article

References (53)

1. Lipsick JS, Wang DM. Transformation by v-Myb. Oncogene 1999; 18: 3047-3055. (Pubitemid 29276544)
2. Ramsay RJ, Gonda TJ. Myb function in normal and cancer cells. Nat Rev Cancer 2008; 8: 523-534. (Pubitemid 351881853)
3. Mucenski ML, McLain K, Kier AB, Swerdlow SH, Schreiner CM, Miller TA et al. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell 1991; 65: 677-689.
4. Emambokus N, Vegiopoulos A, Harman B, Jenkinson E, Anderson G, Frampton J. Progression through key stages of haemtopoiesis is dependent on distinct threshold levels of c-Myb. EMBO J 2003; 22: 4478-4488. (Pubitemid 37087201)
5. Bender TP, Kremer CS, Kraus M, Buch T, Rajewsky K. Critical functions for c-Myb at three checkpoints during thymocyte development. Nat Immunol 2004; 5: 721-729. (Pubitemid 39023304)
6. - mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Proc Natl Acad Sci USA 2004; 101: 6553-6558.
7. Sandberg ML, Sutton SE, Pletcher MT, Wiltshire T, Tarantino LM, Hogenesch JB et al. c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. Dev Cell 2005; 8: 153-166. (Pubitemid 40197733)
8. Thomas MD, Kremer CS, Ravichandran KS, Rajewsky K, Bender TP. c-Myb is critical for B cell development and maintenance of follicular B cells. Immunity 2005; 23: 275-286. (Pubitemid 41317795)
9. Sitzmann J, Noben-Trauth K, Klempnauer KH. Expression of mouse c-myb during embryonic development. Oncogene 1995; 11: 2273-2279. (Pubitemid 26008403)
10. Malaterre J, Carpinelli M, Ernst M, Alexander W, Cooke M, Sutton S et al. c-Myb is required for progenitor cell homeostasis in colonic crypts. Proc Natl Acad Sci USA 2007; 104: 3829-3834. (Pubitemid 47181539)
11. Rushton JJ, Davis LM, Lei W, Mo X, Leutz A, Ness SA. Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins. Oncogene 2003; 22: 308-313. (Pubitemid 36174188)
12. Liu F, Lei W, O'Rourke JP, Ness SA. Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-Myb. Oncogene 2006; 2: 5795-5805.
13. Berge T, Matre V, Brendeford EM, Saether T, Lüscher B, Gabrielsen OS. Revisiting a selection of target genes for the hematopoietic transcription factor c-Myb using chromatin immunoprecipitation and c-Myb knockdown. Blood Cells Mol Dis 2007; 39: 278-286. (Pubitemid 47484463)
14. Ness SA, Marknell A, Graf T. The v-myb oncogene product binds to and activates the promyelocyte-specific mim-1 gene. Cell 1989; 59: 1115-1125. (Pubitemid 20024622)
15. Burk O, Mink S, Ringwald M, Klempnauer K-H. Synergistic activation of the chicken mim-1 gene by v-myb and C/EBP transcription factors. EMBO J 1993; 12: 2027-2038. (Pubitemid 23157719)
16. Mink S, Kerber U, Klempnauer K-H. Interaction of C/EBPbeta and v-Myb is required for synergistic activation of the mim-1 gene. Mol Cell Biol 1996; 16: 1316-1325.
17. Chayka O, Kintscher J, Braas D, Klempnauer K-H. v-Myb mediates cooperation of a cell-specific enhancer with the mim-1 promoter. Mol Cell Biol 2005; 25: 499-511. (Pubitemid 40039838)
18. Plachetka A, Chayka O, Wilczek C, Melnik S, Bonifer C, Klempnauer K-H. C/EBPbeta induces chromatin opening at a cell-type-specific enhancer. Mol Cell Biol 2008; 28: 2102-2112. (Pubitemid 351342639)
19. Wilczek C, Chayka O, Plachetka A, Klempnauer KH. Myb-induced chromatin remodeling at a dual enhancer/promoter element involves non-coding RNA transcription and is disrupted by oncogenic mutations of v-myb. J Biol Chem 2009; 284: 35314-35324.
20. Picman AK. Biological activities of sesquiterpene lactones. Biochem Syst Ecol 1986; 14: 255-281.
21. Schmidt TJ. Toxic activities of sesquiterpene lactonesFstructural and biochemical aspects. Curr Org Chem 1999; 3: 577-605.
22. Schmidt TJ. Structure-activity relationships of sesquiterpene lactones. In: Atta-ur-Rahman Ed. Studies in Natural Products Chemistry, Vol. 33. Elsevier: Amsterdam, 2006; pp 309-392.
23. Ivanova O, Braas D, Klempnauer K-H. Oncogenic point mutations in the Myb DNA-binding domain alter the DNA-binding properties of Myb at a physiological target gene. Nucleic Acids Res 2007; 35: 7237-7247.
24. Schmidt TJ, Brun R, Willuhn G, Khalid SA. Anti-trypanosomal activity of helenalin and some structurally related sesquiterpene lactones. Planta Med 2002; 68: 750-751. (Pubitemid 35013392)
25. Molvaersmyr AK, Saether T, Gilfillan S, Lorenzo PI, Kvaloy H, Matre V et al. A SUMO-regulated activation function controls synergy of c-Myb through a repressor-activator switch leading to differential p300 recruitment. Nucleic Acids Res 2010; 38: 4970-4984.
26. Dahle Ø, Andersen TØ, Nordgård O, Matre V, Del Sal G, Gabrielsen OS. Transactivation properties of c-Myb are critically dependent on two SUMO-1 acceptor sites that are conjugated in a PIASy enhanced manner. Eur J Biochem 2003; 270: 1338-1348. (Pubitemid 36384465)
27. Klempnauer K-H. Methylation-sensitive DNA binding by v-myb and c-myb proteins. Oncogene 1993; 8: 111-115. (Pubitemid 23047236)
28. Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, Kim YS et al. Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: an integrated molecular profiling approach. Prostate 2009; 69: 827-837.
29. Hall IH, Lee KH, Starnes CO, Sumida Y, Wu RY, Waddell TG et al. Anti-inflammatory activity of sesquiterpene lactones and related compounds. J Pharm Sci 1979; 68: 537-542. (Pubitemid 9186368)
30. Heptinstall S, Awang DVC. Feverfew: a review of its History, its biological and medicinal properties, and the status of commerical preparations of the herb (1998). In: Lawson L, Bauer R (eds). Phytomedicines of Europe; ACS Symposium Series, 691. American Chemical Society: Washington, DC, 1998, pp 158-175.
31. Dominguez E, Romo J, Mexicanin I. A new sesquiterpene lactone related to tenulin. Tetrahedron 1963; 19: 1415-1421.
32. Seaman FC. Sesquiterpene lactones as taxonomic characters in the asteraceae. Bot Rev 1982; 48: 121-592.
33. Introna M, Golay J, Frampton J, Nakano T, Ness SA, Graf T. Mutations in v-myb alter the differentiation of myelomonocytic cells transformed by the oncogene. Cell 1990; 63: 1289-1297.
34. Myrset AH, Bostad A, Jamin N, Lirsac PN, Toma F, Gabrielsen OS. DNA and redox state induced conformational changes in the DNA-binding domain of the Myb oncoprotein. EMBO J 1993; 12: 4625-4633. (Pubitemid 23330268)
35. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukaemia stem and progenitor cells. Blood 2005; 105: 4163-4169. (Pubitemid 40720758)
36. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007; 110: 4427-4435. (Pubitemid 351377809)
37. Nasim S, Crooks PA. Antileukemic activity of aminoparthenolide analogs. Bioorg Med Chem Lett 2008; 18: 3870-3873.
38. Lyß G, Knorre A, Schmidt TJ, Pahl HL, Merfort I. The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65. J Biol Chem 1998; 273: 33508-33516. (Pubitemid 29005734)
39. Rüngeler P, Castro V, Mora G, Gören N, Vichnewski W, Pahl HL et al. Inhibition of transcription factor NF-kappa B by sesquiterpene lactones - a proposed molecular mechanism of action. Bioorg Med Chem 1999; 7: 2343-2352. (Pubitemid 30122736)
40. Bedoya LM, Abad MJ, Bermejo P. The role of parthenolide in intracellular signaling processes: review of current knowledge. Curr Signal Transduct Ther 2008; 3: 82-87.
41. Anfossi G, Gewirtz AM, Calabretta B. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc Natl Acad Sci USA 1989; 86: 3379-3383. (Pubitemid 19129615)
42. Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D et al. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA 1991; 88: 2351-2355. (Pubitemid 21916414)
43. Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela JM, Dik WA et al. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood 2007; 110: 1251-1261. (Pubitemid 47281423)
44. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 2007; 39: 593-595. (Pubitemid 46676109)
45. Biroccio A, Benassi B, D'Agnano I, D'Angelo C, Buglioni S, Mottolese M et al. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol 2001; 158: 1289-1299. (Pubitemid 32281293)
46. Hugo H, Cures A, Suraweera N, Drabsch Y, Purcell D, Mantamadiotis T et al. Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers. Genes Chromosomes Cancer 2006; 45: 1143-1154. (Pubitemid 44763442)
47. Guérin M, Sheng ZM, Andrieu N, Riou G. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 1990; 5: 131-135. (Pubitemid 20044814)
48. Drabsch Y, Hugo H, Zhang R, Dowhan DH, Miao YR, Gewirtz AM et al. Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells. Proc Natl Acad Sci USA 2007; 104: 13762-13767. (Pubitemid 350003394)
49. Nicolau M, Levine AJ, Carlsson G. Topology based data analysis identifies a subgroup of breast cancers with a unique mutationaol profile and excellent survival. Proc Natl Acad Sci USA 2011; 108: 7265-7270.
50. Thorner AR, Parker JS, Hoadley KA, Perou CM. Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. PLoS One 2010; 5: e13073.
51. Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast, and head and neck. Proc Natl Acad Sci USA 2009; 106: 18740-18744.
52. Opalinska JB, Gewirtz AM. Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov 2002; 1: 503-514. (Pubitemid 37361504)
53. Litvak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001; 25: 402-408. (Pubitemid 34164012)